Related Experiment Videos
Protein C and antithrombin III in polytransfused thalassemic patients
Insights
Beta-thalassemia major patients often have low protein C (PC) and antithrombin III (AT III) levels, increasing risks for CNS thromboembolic lesions. However, other factors may counteract this risk in these patients.
Area of Science:
- Hematology
- Thrombosis
- Genetics
Background:
- Beta-thalassemia major is a severe inherited blood disorder.
- Patients with beta-thalassemia major are at risk for thromboembolic events.
- Antithrombotic proteins like protein C (PC) and antithrombin III (AT III) play a crucial role in hemostasis.
Purpose of the Study:
- To investigate the association between deficiencies in protein C (PC) and antithrombin III (AT III) and the pathogenesis of CNS thromboembolic lesions in beta-thalassemia major.
- To explore the correlation of PC and AT III levels with clinical parameters in these patients.
Main Methods:
- Studied 74 patients with beta-thalassemia major.
- Measured levels of protein C (PC) and antithrombin III (AT III).
- Analyzed correlations between PC/AT III levels and various clinical and laboratory parameters including age, iron status, liver function, and coagulation tests.
Main Results:
- Significantly lower PC levels were observed in 70 patients; lower AT III activity in 41 patients.
- Lowest PC and AT III values were found in older, splenectomized patients.
- PC levels correlated significantly with age, iron load, ferritin, albumin, prothrombin time, fibrinogen, and transaminases (GPT).
- Only 2 patients experienced CNS thromboembolic complications, suggesting a complex hemostatic balance.
Conclusions:
- Deficiencies in PC and AT III are common in beta-thalassemia major.
- While low PC and AT III levels suggest a prothrombotic state, other factors like those seen in chronic liver disease may mitigate this risk.
- The pathogenesis of CNS thromboembolic lesions in beta-thalassemia major is multifactorial.
Abstract:
Seventy-four patients with beta-thalassemia major were studied to test the hypothesis that a deficiency of protein C (PC) and antithrombin III (AT III), both antithrombotic proteins, could contribute to the pathogenesis of CNS thromboembolic lesions. In 70 patients, PC levels were found to be significantly lower than normal, whereas AT III activity was found to be lower only in 41 patients. The lowest values of PC and AT III were found in older splenectomized patients, a low PC value only was found in chronic hepatitis patients. Prothrombin time and fibrinogen were found to be particularly abnormal in patients with chronic hepatitis and without spleen. A relatively poor correlation was observed between PC and AT III (p less than 0.02). PC correlated with age (p less than 0.001), transfusional iron (p less than 0.001) and ferritin (p less than 0.001). It also correlated with serum albumin (p less than 0.001), prothrombin time (p less than 0.001) and fibrinogen (p less than 0.02) and with serum transaminases (GPT) (p less than 0.001). The same indexes correlated less significantly with AT III activity. Nevertheless, only 2 of our patients had CNS thromboembolic complications. It is probable that low clotting factors, hyperfibrinolysis and thrombocytopenia (which are common in chronic liver disease) could have the opposite effect on hemostasis from that of low levels of anticoagulant proteins such as PC and AT III.